Astria Therapeutics Inc现已在欧盟招募HAE患者参与三期Alpha-Orbit临床试验

美股速递
Oct 02, 2025

Astria Therapeutics Inc宣布,目前正在欧盟地区招募遗传性血管性水肿(HAE)患者,以参与其关键性的三期Alpha-Orbit临床试验。

该试验标志着公司在HAE治疗药物开发方面迈出的重要一步,将为欧盟地区的HAE患者提供参与前沿治疗研究的机会。三期临床试验是药物开发过程中的关键阶段,旨在进一步验证治疗方案的安全性和有效性。

通过在欧盟启动患者招募工作,Astria Therapeutics Inc进一步扩大了其Alpha-Orbit试验的覆盖范围,为更多HAE患者带来了参与这项重要临床研究的可能性。

Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.

Most Discussed

  1. 1
     
     
     
     
  2. 2
     
     
     
     
  3. 3
     
     
     
     
  4. 4
     
     
     
     
  5. 5
     
     
     
     
  6. 6
     
     
     
     
  7. 7
     
     
     
     
  8. 8
     
     
     
     
  9. 9
     
     
     
     
  10. 10